ES2338919T3 - Anticuerpos anti-receptor ccr7 para el tratamiento del cancer. - Google Patents

Anticuerpos anti-receptor ccr7 para el tratamiento del cancer. Download PDF

Info

Publication number
ES2338919T3
ES2338919T3 ES06776128T ES06776128T ES2338919T3 ES 2338919 T3 ES2338919 T3 ES 2338919T3 ES 06776128 T ES06776128 T ES 06776128T ES 06776128 T ES06776128 T ES 06776128T ES 2338919 T3 ES2338919 T3 ES 2338919T3
Authority
ES
Spain
Prior art keywords
cells
ccr7
antibody
antibodies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06776128T
Other languages
English (en)
Spanish (es)
Inventor
Cecilia Muñoz Calleja
Manuel Jesus Alfonso Perez
Sonia Lopez Giral
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Application granted granted Critical
Publication of ES2338919T3 publication Critical patent/ES2338919T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES06776128T 2005-07-06 2006-07-05 Anticuerpos anti-receptor ccr7 para el tratamiento del cancer. Active ES2338919T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOEP2005/007371 2005-07-06
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
ES2338919T3 true ES2338919T3 (es) 2010-05-13

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06776128T Active ES2338919T3 (es) 2005-07-06 2006-07-05 Anticuerpos anti-receptor ccr7 para el tratamiento del cancer.

Country Status (16)

Country Link
US (1) US8066996B2 (https=)
EP (1) EP1904102B1 (https=)
JP (1) JP5249025B2 (https=)
KR (1) KR20080030655A (https=)
CN (1) CN101257923A (https=)
AT (1) ATE453407T1 (https=)
AU (1) AU2006265281C1 (https=)
BR (1) BRPI0612632A2 (https=)
CA (1) CA2614080C (https=)
DE (1) DE602006011466D1 (https=)
DK (1) DK1904102T3 (https=)
ES (1) ES2338919T3 (https=)
IL (1) IL188594A (https=)
PT (1) PT1904102E (https=)
RU (1) RU2404808C2 (https=)
WO (2) WO2007003216A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
WO2011040428A1 (ja) * 2009-09-29 2011-04-07 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
AU2011309114B2 (en) * 2010-09-28 2015-03-19 Nb Health Laboratory Co., Ltd. Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP2970483A2 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
JP6618191B2 (ja) * 2014-03-27 2019-12-11 国立研究開発法人医薬基盤・健康・栄養研究所 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
BR112018002877A2 (en) 2015-08-10 2018-11-06 Pepmab B.V. humanized ccr7 receptor antibodies
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20220064311A1 (en) * 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
US7807784B2 (en) * 2003-06-11 2010-10-05 The University Of Chicago Increased T-cell tumor infiltration by mutant LIGHT

Also Published As

Publication number Publication date
DE602006011466D1 (de) 2010-02-11
RU2008104420A (ru) 2009-08-20
AU2006265281C1 (en) 2012-11-15
AU2006265281B2 (en) 2012-03-01
BRPI0612632A2 (pt) 2012-01-03
US20090123483A1 (en) 2009-05-14
ATE453407T1 (de) 2010-01-15
CN101257923A (zh) 2008-09-03
JP2008545000A (ja) 2008-12-11
JP5249025B2 (ja) 2013-07-31
EP1904102B1 (en) 2009-12-30
IL188594A (en) 2012-02-29
CA2614080A1 (en) 2007-01-11
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
DK1904102T3 (da) 2010-04-19
IL188594A0 (en) 2008-04-13
CA2614080C (en) 2014-08-26
KR20080030655A (ko) 2008-04-04
WO2007003216A1 (en) 2007-01-11
EP1904102A1 (en) 2008-04-02
PT1904102E (pt) 2010-03-29
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
CN114555123B (zh) 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
US10017567B2 (en) Treatment of cancer with anti-LAP monoclonal antibodies
ES2338919T3 (es) Anticuerpos anti-receptor ccr7 para el tratamiento del cancer.
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
CN1981868A (zh) 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
CN101679522A (zh) 肿瘤微环境的调控
CN114401990A (zh) 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途
BR112020013925A2 (pt) molécula de primeiro anticorpo, composição farmacêutica, kit para uso no tratamento de um câncer negativo para fc¿riib, uso, e, método para tratamento de um câncer negativo para fc¿riib.
CA3096705A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
AU2019266203A1 (en) Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3211203A1 (en) Methods and materials for treating clonal t cell expansions
CN114729045A (zh) 对糖基化的ctla-4特异性的抗体及其使用方法
KR20220151172A (ko) 항-gitr 항체 및 이의 용도
US12129305B2 (en) Targeting CLPTM1L for treatment and prevention of cancer
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
CN119677779A (zh) 抗核仁磷蛋白1抗体和抗体缀合物组合治疗
CN121511261A (zh) 抗组织蛋白酶-d抗体
HK40113788A (zh) 抗cd39抗体及其用途
HK40109251A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
KR20220088438A (ko) 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
HK40042823A (en) Anti-cd73 antibodies and methods of use thereof